{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:12:47Z","timestamp":1769127167004,"version":"3.49.0"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T00:00:00Z","timestamp":1692662400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Diffuse interstitial myocardial fibrosis is a key common pathological manifestation in hypertensive heart disease (HHD) progressing to heart failure (HF). Angiotensin receptor\u2013neprilysin inhibitors (ARNi), now a front-line treatment for HF, confer benefits independent of blood pressure, signifying a multifactorial mode of action beyond hemodynamic regulation. We aim to test the hypothesis that compared with angiotensin II receptor blockade (ARB) alone, ARNi is more effective in regressing diffuse interstitial myocardial fibrosis in HHD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Role of ARNi in Ventricular Remodeling in Hypertensive LVH (REVERSE-LVH) is a prospective, randomized, open-label, blinded endpoint (PROBE) clinical trial. Adults with hypertension and left ventricular hypertrophy (LVH) according to Asian sex- and age-specific thresholds on cardiovascular magnetic resonance (CMR) imaging are randomized to treatment with either sacubitril\/valsartan (an ARNi) or valsartan (an ARB) in 1:1 ratio for a duration of 52 weeks, at the end of which a repeat CMR is performed to assess differential changes from baseline between the two groups. The primary endpoint is the change in CMR-derived diffuse interstitial fibrosis volume. Secondary endpoints include changes in CMR-derived left ventricular mass, volumes, and functional parameters. Serum samples are collected and stored to assess the effects of ARNi, compared with ARB, on circulating biomarkers of cardiac remodeling. The endpoints will be analyzed with reference to the corresponding baseline parameters to evaluate the therapeutic effect of sacubitril\/valsartan vs. valsartan.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>REVERSE-LVH will examine the anti-fibrotic potential of sacubitril\/valsartan and will offer mechanistic insights into the clinical benefits of sacubitril\/valsartan in hypertension in relation to cardiac remodeling. Advancing the knowledge of the pathophysiology of HHD will consolidate effective risk stratification and personalized treatment through a multimodal manner integrating complementary CMR and biomarkers into the conventional care approach.<\/jats:p><jats:p><jats:bold>Clinical Trial Registration<\/jats:bold>: <jats:ext-link>ClinicalTrials.gov<\/jats:ext-link>, identifier, NCT03553810.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcvm.2023.1248468","type":"journal-article","created":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T13:55:51Z","timestamp":1692712551000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["Sacubitril\/valsartan versus valsartan in regressing myocardial fibrosis in hypertension: a prospective, randomized, open-label, blinded endpoint clinical trial protocol"],"prefix":"10.3389","volume":"10","author":[{"given":"Vivian","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qishi","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Desiree-Faye","family":"Toh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chee Jian","family":"Pua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer A.","family":"Bryant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi-Hang","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart A.","family":"Cook","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javed","family":"Butler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"D\u00edez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. Mark","family":"Richards","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thu-Thao","family":"Le","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Calvin W. L.","family":"Chin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,8,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/ncpcardio0158","article-title":"Mechanisms of disease: pathologic structural remodeling is more than adaptive hypertrophy in hypertensive heart disease","volume":"2","author":"D\u00edez","year":"2005","journal-title":"Nat Clin Pract Cardiovas Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.yjmcc.2016.06.001","article-title":"Physiological and pathological cardiac hypertrophy","volume":"97","author":"Shimizu","year":"2016","journal-title":"J Mol Cell Cardiol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1093\/cvr\/cvaa023","article-title":"Coronary microvascular dysfunction in hypertrophy and heart failure","volume":"116","author":"Camici","year":"2020","journal-title":"Cardiovasc Res"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1161\/01.cir.102.12.1388","article-title":"Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease","volume":"102","author":"Brilla","year":"2000","journal-title":"Circulation"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.1161\/01.cir.0000017264.66561.3d","article-title":"Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients","volume":"105","author":"D\u00edez","year":"2002","journal-title":"Circulation"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/S0140-6736(09)61966-8","article-title":"Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study","volume":"375","author":"Ruilope","year":"2010","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/nejmoa1409077","article-title":"Angiotensin\u2013neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1056\/nejmoa1812851","article-title":"Angiotensin\u2013neprilysin inhibition in acute decompensated heart failure","volume":"380","author":"Velazquez","year":"2019","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1016\/S0140-6736(12)61227-6","article-title":"The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial","volume":"380","author":"Solomon","year":"2012","journal-title":"Lancet"},{"key":"B10","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1161\/CIRCHEARTFAILURE.114.001427","article-title":"Elevation in high-sensitivity troponin T in heart failure and preserved ejection fraction and influence of treatment with the angiotensin receptor neprilysin inhibitor LCZ696","volume":"7","author":"Jhund","year":"2014","journal-title":"Circ Heart Fail"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e137","DOI":"10.1161\/cir.0000000000000509","article-title":"2017 ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines and the heart failure society of America","volume":"136","author":"Yancy","year":"2017","journal-title":"Circulation"},{"key":"B13","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1002\/ejhf.474","article-title":"LCZ696, An angiotensin receptor-neprilysin inhibitor, improves cardiac function with the attenuation of fibrosis in heart failure with reduced ejection fraction in streptozotocin-induced diabetic mice","volume":"18","author":"Suematsu","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"B14","doi-asserted-by":"publisher","first-page":"3308","DOI":"10.1093\/eurheartj\/ehx525","article-title":"The effect of sacubitril\/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: the results of a randomized, double-blind, active-controlled study","volume":"38","author":"Schmieder","year":"2017","journal-title":"Eur Heart J"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1097\/hjh.0000000000003430","article-title":"Effect of sacubitril\/valsartan or valsartan on ventricular remodeling and myocardial fibrosis in perimenopausal women with hypertension","volume":"41","author":"Chen","year":"2023","journal-title":"J Hypertens"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1016\/j.jcmg.2016.10.007","article-title":"Myocardial fibrosis and cardiac decompensation in aortic stenosis","volume":"10","author":"Chin","year":"2017","journal-title":"JACC Cardiovasc Imaging"},{"key":"B17","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s12968-016-0236-3","article-title":"Cardiovascular magnetic resonance reference ranges for the heart and aorta in Chinese at 3\u2005T","volume":"18","author":"Le","year":"2016","journal-title":"J Cardiovasc Magn Reson"},{"key":"B18","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1161\/hypertensionaha.113.02002","article-title":"Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension","volume":"63","author":"Kario","year":"2014","journal-title":"Hypertension"},{"key":"B19","doi-asserted-by":"publisher","first-page":"S73","DOI":"10.1038\/sj.jhh.1000991","article-title":"Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension","volume":"14","author":"Israili","year":"2000","journal-title":"J Hum Hypertens"},{"key":"B20","author":"Sanders","year":""},{"key":"B21","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/jch.12237","article-title":"Clinical practice guidelines for the management of hypertension in the community","volume":"16","author":"Weber","year":"2013","journal-title":"J Clin Hypertens"},{"key":"B22","year":""},{"key":"B23","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s12968-017-0413-z","article-title":"Fractal analysis of left ventricular trabeculations is associated with impaired myocardial deformation in healthy Chinese","volume":"19","author":"Cai","year":"2017","journal-title":"J Cardiovasc Magn Reson"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1161\/HYPERTENSIONAHA.122.19225","article-title":"Markers of focal and diffuse nonischemic myocardial fibrosis are associated with adverse cardiac remodeling and prognosis in patients with hypertension: the REMODEL study","volume":"79","author":"Iyer","year":"2022","journal-title":"Hypertension"},{"key":"B25","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1093\/ehjci\/jeaa040","article-title":"The remodelling index risk stratifies patients with hypertensive left ventricular hypertrophy","volume":"22","author":"Le","year":"2021","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"B26","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1161\/circheartfailure.114.001785","article-title":"Angiotensin receptor neprilysin inhibitor LCZ696 attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy","volume":"8","author":"von Lueder","year":"2015","journal-title":"Circ Heart Fail"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/nejmoa1908655","article-title":"Angiotensin\u2013neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1016\/j.jacc.2003.12.052","article-title":"Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure","volume":"43","author":"L\u00f3pez","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2940","DOI":"10.1161\/circulationaha.105.571653","article-title":"Mineralocorticoid receptor antagonism ameliorates left ventricular diastolic dysfunction and myocardial fibrosis in mildly symptomatic patients with idiopathic dilated cardiomyopathy","volume":"112","author":"Izawa","year":"2005","journal-title":"Circulation"},{"key":"B30","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3109\/08037059209077502","article-title":"Prospective randomized open blinded End-point (PROBE) study: a novel design for intervention trials","volume":"1","author":"Hansson","year":"1992","journal-title":"Blood Press"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2023.1248468\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T13:55:54Z","timestamp":1692712554000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2023.1248468\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,22]]},"references-count":30,"alternative-id":["10.3389\/fcvm.2023.1248468"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2023.1248468","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,22]]},"article-number":"1248468"}}